AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2114989 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 7
Study 226565 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 320 mg
Number of subjects: 12
Study 226565 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 960 mg
Number of subjects: 12
Study 226565 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 12
Study 31518936 — intervention group
Group type: EXPERIMENTAL
Intervention: LPG cookstove intervention
Number of subjects: 260
Study 31518936 — intervention group
Group type: COMPARATOR
Intervention: 3-stone cookstove (baseline)
Number of subjects: 260
Study 27839894 — intervention group
Group type: EXPERIMENTAL
Intervention: ClearGuard HD Antimicrobial Barrier Caps
Number of subjects: 2470
Study 27839894 — intervention group
Group type: EXPERIMENTAL
Intervention: ClearGuard HD Antimicrobial Barrier Caps (sustained use)
Number of subjects: 2470
Study 27839894 — intervention group
Group type: COMPARATOR
Intervention: Standard CVC caps
Number of subjects: 2470
Study 25316180 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive wrist extension (30 repetitions with maximal isometric contraction for 6 minutes)
Number of subjects: 28
Study 25316180 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 28
Study 25316180 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive wrist extension
Number of subjects: 28
Study 25316180 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 23877689 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% paromomycin
Number of subjects: 0
Study 23877689 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% paromomycin plus 0.5% gentamicin (WR 279,396)
Number of subjects: 0
Study 21452931 — intervention group
Group type: EXPERIMENTAL
Intervention: Noble metal alloy-coated latex catheter
Number of subjects: 439
Study 21452931 — intervention group
Group type: COMPARATOR
Intervention: Silicone catheter
Number of subjects: 439
Study 19296248 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive enteral nutrition (EN) - 1000 ml Nutrison Multi Fibre (4184 kJ/L) for 3 days before surgery
Number of subjects: 0
Study 19296248 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preventive enteral nutrition)
Number of subjects: 0
Study 19296248 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive enteral nutrition (EN)
Number of subjects: 0
Study 17768771 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (1.5 pmol/kg/min)
Number of subjects: 13
Study 17768771 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl)
Number of subjects: 13
Study 15170367 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 250 mg single dose
Number of subjects: 219
Study 15170367 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 250 mg multiple doses (once monthly)
Number of subjects: 219
Study 15170367 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 250 mg (once monthly)
Number of subjects: 219
Study 11213882 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 59
Study 11213882 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 59
Study 11798226 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based pain management guidelines
Number of subjects: 0
Study 11798226 — intervention group
Group type: EXPERIMENTAL
Intervention: Research and systematic reviews
Number of subjects: 0
Study 9301991 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin-omeprazole dual therapy
Number of subjects: 22
Study 9301991 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole therapy alone
Number of subjects: 22
Study 8330823 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine
Number of subjects: 191
Study 8330823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 3631465 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine/promethazine with fentanyl
Number of subjects: 20
Study 3631465 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 20
Study 2673883 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethynyloestradiol
Number of subjects: 20
Study 2673883 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone
Number of subjects: 20
Study 2673883 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined norgestrel and ethynyloestradiol
Number of subjects: 20
Study 2673883 — intervention group
Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 20
Study 31229200 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth-opening intervention with remote support via telephone
Number of subjects: 60
Study 31229200 — intervention group
Group type: COMPARATOR
Intervention: Active control group (no remote support)
Number of subjects: 60
Study 28133906 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus with low-exposure tacrolimus discontinued by month 4
Number of subjects: 188
Study 28133906 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus-based therapy
Number of subjects: 188
Study 28133906 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 188
Study 28133906 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 188
Study 24942409 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) 1.4 ± 0.5 mg/kg
Number of subjects: 102
Study 24942409 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (MPH) 52.4 ± 16.6 mg
Number of subjects: 102
Study 23423753 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 0
Study 23423753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21914270 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-free calf blood extract eye gel (3 times per day for three months)
Number of subjects: 49
Study 21914270 — intervention group
Group type: COMPARATOR
Intervention: No treatment (no drug treated group)
Number of subjects: 49
Study 19411787 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral nursing intervention (2 hr/week for 6 weeks)
Number of subjects: 71
Study 17561724 — intervention group
Group type: EXPERIMENTAL
Intervention: Sartan
Number of subjects: 0
Study 17561724 — intervention group
Group type: COMPARATOR
Intervention: Beta-blocker
Number of subjects: 0
Study 15084068 — intervention group
Group type: EXPERIMENTAL
Intervention: 11C-acetate
Number of subjects: 6
Study 15084068 — intervention group
Group type: COMPARATOR
Intervention: nontumor liver tissue
Number of subjects: 6
Study 11174292 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sodium thiosulfate solution spray
Number of subjects: 120
Study 11174292 — intervention group
Group type: COMPARATOR
Intervention: Maalox (aluminum‐magnesium hydroxide gel)
Number of subjects: 120
Study 11174292 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 120
Study 9433426 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 325
Study 9433426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study 8948741 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatine infusion with 3.5% urea bridges during normovolemic intentional hemodilution
Number of subjects: 0
Study 8948741 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid infusion
Number of subjects: 0
Study 2517008 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine 1 mg
Number of subjects: 244
Study 2517008 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 244
Study 2517008 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 244
Study 795443 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid analogue
Number of subjects: 12
Study 795443 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 12
Study 31009034 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (2 actuations, 200 μg)
Number of subjects: 484
Study 31009034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 484
Study 29190720 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean/low-carbohydrate diet (MED/LC) with 28g·day-1 of walnuts + moderate intense physical activity (PA+)
Number of subjects: 277
Study 29190720 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (LF) + moderate intense physical activity (PA+)
Number of subjects: 277
Study 29190720 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean/low-carbohydrate diet (MED/LC) with 28g·day-1 of walnuts + non-physical activity (PA-)
Number of subjects: 277
Study 29190720 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (LF) + non-physical activity (PA-)
Number of subjects: 277
Study 25551626 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippotherapy (30 minutes twice weekly for 8 consecutive weeks)
Number of subjects: 92
Study 25551626 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 92
Study 24064879 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% FIO2 intraoperatively and for 2 hours afterward
Number of subjects: 222
Study 24064879 — intervention group
Group type: COMPARATOR
Intervention: 30% FIO2 during the same period
Number of subjects: 222
Study 21954342 — intervention group
Group type: EXPERIMENTAL
Intervention: Telfa AMD(®)
Number of subjects: 32
Study 21954342 — intervention group
Group type: COMPARATOR
Intervention: Bactigras(®)
Number of subjects: 32
Study 19085221 — intervention group
Group type: EXPERIMENTAL
Intervention: Art therapy session
Number of subjects: 79
Study 19085221 — intervention group
Group type: COMPARATOR
Intervention: Videotape about art therapy
Number of subjects: 79
Study 17045803 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent motor task (carrying a tray with marbles)
Number of subjects: 48
Study 17045803 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent motor task (carrying a tray without marbles)
Number of subjects: 48
Study 17045803 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive task (repeating a series of digits forwards or backwards)
Number of subjects: 48
Study 17045803 — intervention group
Group type: COMPARATOR
Intervention: Walking alone (no concurrent task)
Number of subjects: 48
Study 15090936 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (100 mg/day for days 1-14; 100 or 200 mg/day for days 15-28)
Number of subjects: 11
Study 15090936 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 11
Study 11466245 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol alginate once daily
Number of subjects: 235
Study 11466245 — intervention group
Group type: COMPARATOR
Intervention: Standard carteolol solution, twice daily
Number of subjects: 235
Study 9710300 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3.3 mg/kg, equivalent to 2 to 3 cups of coffee)
Number of subjects: 0
Study 9710300 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine plus tasks (behavioral stress)
Number of subjects: 0
Study 9710300 — intervention group
Group type: COMPARATOR
Intervention: Tasks alone (mental stressor and psychomotor task)
Number of subjects: 0
Study 8199744 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy
Number of subjects: 323
Study 8199744 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine prophylaxis
Number of subjects: 323
Study 2846002 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 0
Study 2846002 — intervention group
Group type: COMPARATOR
Intervention: Sympathomimetics
Number of subjects: 0
Study 2846002 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (oral or parenteral)
Number of subjects: 0
Study 30578392 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib therapy
Number of subjects: 294
Study 28245383 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment group (hydroxyurea plus IFN-alpha)
Number of subjects: 50
Study 28245383 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment group (hydroxyurea)
Number of subjects: 50
Study 26854931 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized disease risk feedback
Number of subjects: 497
Study 26854931 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary risk assessments (one family member)
Number of subjects: 497
Study 24929889 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestogen-only pills (POPs)
Number of subjects: 168
Study 24929889 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid access to family planning clinic (FPC)
Number of subjects: 168
Study 24929889 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 168
Study 22381428 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchman device implantation with peri-device flow
Number of subjects: 0
Study 19580584 — intervention group
Group type: EXPERIMENTAL
Intervention: MEL 308 nm once-weekly and oral vitamin E
Number of subjects: 48
Study 19580584 — intervention group
Group type: EXPERIMENTAL
Intervention: MEL 308 nm once-weekly combined with khellin 4% ointment and oral vitamin E
Number of subjects: 48
Study 19580584 — intervention group
Group type: COMPARATOR
Intervention: Oral vitamin E (control group)
Number of subjects: 48
Study 17924873 — intervention group
Group type: EXPERIMENTAL
Intervention: 303 Algorithm group (self-titration dosing guideline)
Number of subjects: 5604
Study 17924873 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care group (physician-driven adjustments)
Number of subjects: 5604
Study 17924873 — intervention group
Group type: EXPERIMENTAL
Intervention: 303 Algorithm group
Number of subjects: 5604
Study 17924873 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care group
Number of subjects: 5604
Study 15356670 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (herbal formulation containing ephedrine, caffeine, and other ingredients)
Number of subjects: 102
Study 15356670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 11368462 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 36
Study 11368462 — intervention group
Group type: COMPARATOR
Intervention: Placebo 5 mg
Number of subjects: 36
Study 9529020 — intervention group
Group type: EXPERIMENTAL
Intervention: MAID chemotherapy (doxorubicin, dacarbazine, ifosfamide, and mesna)
Number of subjects: 69
Study 9529020 — intervention group
Group type: EXPERIMENTAL
Intervention: MAID chemotherapy
Number of subjects: 69
Study 8053040 — intervention group
Group type: EXPERIMENTAL
Intervention: Distribution of recruitment brochures 2 weeks in advance of blood drives and provision of temporary deferral brochures during health history taking (Experimental Group)
Number of subjects: 24
Study 8053040 — intervention group
Group type: COMPARATOR
Intervention: Control group (no brochures distributed)
Number of subjects: 24
Study 2657839 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (mean dose 29.5 mg/day)
Number of subjects: 60
Study 2657839 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (mean dose 140 mg/day)
Number of subjects: 60
Study 2657839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2657839 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone and Imipramine
Number of subjects: 60
Study 30284910 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastrojejunostomy (ReY)
Number of subjects: 64
Study 30284910 — intervention group
Group type: COMPARATOR
Intervention: Billroth II gastrojejunostomy (BII)
Number of subjects: 64
Study 28963129 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity exercise (150-min intermittent)
Number of subjects: 42
Study 28963129 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise (150-min intermittent)
Number of subjects: 42
Study 28963129 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise (150-min intermittent)
Number of subjects: 42
Study 28963129 — intervention group
Group type: EXPERIMENTAL
Intervention: On-court training
Number of subjects: 42
Study 24535937 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine + NY-ESO-1 vaccine + doxorubicin liposome chemotherapy
Number of subjects: 12
Study 24345099 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial approach
Number of subjects: 200
Study 24345099 — intervention group
Group type: COMPARATOR
Intervention: Vascular closure device (femoral access)
Number of subjects: 200
Study 20672721 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home whitening (HW) with 10% carbamide peroxide overnight
Number of subjects: 20
Study 20672721 — intervention group
Group type: COMPARATOR
Intervention: In-office whitening (OW) with 25% hydrogen peroxide
Number of subjects: 20
Study 20672721 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference and recommendation
Number of subjects: 20
Study 18793913 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual triazolam 0.25 mg
Number of subjects: 58
Study 18793913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 15728060 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 0
Study 15728060 — intervention group
Group type: COMPARATOR
Intervention: 5 mL of epidural saline
Number of subjects: 0
Study 12503978 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (16 mg daily)
Number of subjects: 60
Study 12503978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10841179 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1200 mg) plus Vitamin D (800 IU)
Number of subjects: 148
Study 10841179 — intervention group
Group type: COMPARATOR
Intervention: Calcium (1200 mg)
Number of subjects: 148
Study 8853667 — intervention group
Group type: EXPERIMENTAL
Intervention: Tylenol Extended Relief (ER APAP)
Number of subjects: 14
Study 8853667 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release acetaminophen (IR APAP)
Number of subjects: 14
Study 8422668 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant human erythropoietin (r‐hEPO) administration (3000 IU, 12 cases; 6000 IU, 14 cases), three times a week
Number of subjects: 26
Study 8422668 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant human erythropoietin (r‐hEPO) administration
Number of subjects: 26
Study 2873601 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluperlapine
Number of subjects: 12
Study 2873601 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 12
Study 31291158 — intervention group
Group type: EXPERIMENTAL
Intervention: Anonymous BabyCenter.com loss support group
Number of subjects: 90
Study 31291158 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed Facebook loss group
Number of subjects: 90
Study 31291158 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 30453403 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone dust collector
Number of subjects: 64
Study 30453403 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 64
Study 30453403 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study 24525155 — intervention group
Group type: EXPERIMENTAL
Intervention: HTUPA (25 mg bolus)
Number of subjects: 221
Study 24525155 — intervention group
Group type: COMPARATOR
Intervention: rt-PA (standard protocol)
Number of subjects: 221
Study 22647414 — intervention group
Group type: COMPARATOR
Intervention: No anemia (n=712)
Number of subjects: 1013
Study 22647414 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild anemia (n=141)
Number of subjects: 1013
Study 22647414 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-severe anemia (n=160)
Number of subjects: 1013
Study 20116842 — intervention group
Group type: EXPERIMENTAL
Intervention: No sedation (n=70 patients)
Number of subjects: 140
Study 20116842 — intervention group
Group type: COMPARATOR
Intervention: Interrupted sedation (20 mg/mL propofol for 48 h, 1 mg/mL midazolam thereafter) (n=70, control group)
Number of subjects: 140
Study 20116842 — intervention group
Group type: EXPERIMENTAL
Intervention: No sedation
Number of subjects: 140
Study 17573510 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole 800 mg/d, administered in divided doses for 34 to 365 days
Number of subjects: 15
Study 17573510 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole treatment
Number of subjects: 15
Study 17573510 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole treatment for >or= 12 months
Number of subjects: 15
Study 15857324 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa and carbidopa
Number of subjects: 24
Study 15857324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12242060 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (initiated at 2.5 mg/day, with increases allowed every 3 to 4 days up to a maximum of 15 mg/day)
Number of subjects: 0
Study 12242060 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 12242060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26135318 — intervention group
Group type: EXPERIMENTAL
Intervention: Indian F(ab')2 snake antivenom
Number of subjects: 75
Study 8580279 — intervention group
Group type: EXPERIMENTAL
Intervention: Lintopride 0.1 mg/kg
Number of subjects: 8
Study 8580279 — intervention group
Group type: EXPERIMENTAL
Intervention: Lintopride 0.3 mg/kg
Number of subjects: 8
Study 8580279 — intervention group
Group type: EXPERIMENTAL
Intervention: Lintopride 0.5 mg/kg
Number of subjects: 8
Study 8580279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2571184 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretin (0.05 CU kg‐1h‐1)
Number of subjects: 10
Study 2571184 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (60 pmol kg‐1h‐1)
Number of subjects: 10
Study 2571184 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretin and Somatostatin (combined infusion)
Number of subjects: 10
Study 2571184 — intervention group
Group type: COMPARATOR
Intervention: Control (Pentagastrin-stimulated acid secretion)
Number of subjects: 10
Study 590601 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (2 g single dose)
Number of subjects: 100
Study 590601 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (2 g single dose)
Number of subjects: 100